文献速递MDS 与骨髓增殖性肿瘤白血病

JAK2外显子13插入缺失驱动致癌转化并与慢性嗜酸性白血病和真性红细胞增多症相关

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
PubMed 文献 · Blood · 2019-01-01

该研究描述了一种位于JAK2 JH2结构域的新型复发突变,表现为Leu583-Ala586DelInsSer/Gln/Pro。4例携带者均有嗜酸性粒细胞增多,其中2例Leu583-Ala586DelInsSer同时符合PV和CEL诊断标准。功能研究显示该突变通过类似JAK2V617F的机制激活STAT5和ERK,转化Ba/F3细胞,且能不依赖配体激活β共同链家族细胞因子受体信号,对IL-5R效应最大。

要点

  • JAK2ex13InDel是PV/CEL重叠MPN的新驱动突变。
  • 该突变不依赖外源性同二聚体1型细胞因子受体即可转化Ba/F3细胞。
  • 对不明原因嗜酸性粒细胞增多者行靶向NGS可能发现更多病例。

核心结论

  • JAK2ex13InDel是驱动致癌转化并与PV/CEL重叠MPN相关的新型复发突变。

研究设计与样本

  • 研究描述了4例携带JAK2 JH2结构域Leu583-Ala586DelInsSer/Gln/Pro突变的患者,并进行计算和功能研究。

主要发现

  • 所有4例患者均有嗜酸性粒细胞增多,2例Leu583-Ala586DelInsSer满足PV和CEL诊断标准。
  • Leu583-Ala586DelInsSer通过类似JAK2V617F的机制 deregulates JAK2,激活STAT5和ERK,并转化Ba/F3细胞至生长因子非依赖。
  • 与JAK2V617F不同,JAK2ex13InDel不需要外源性同二聚体1型细胞因子受体即可转化Ba/F3细胞,并能不依赖配体激活IL-3R、IL-5R和GM-CSF受体信号,对IL-5R效应最大。

关键数值与推荐

  • 2例Leu583-Ala586DelInsSer患者同时符合PV和CEL诊断标准。

临床怎么用

  • 识别这种新的PV/CEL重叠MPN具有重要临床意义,因PV和CEL患者血栓风险高,可能需要同时降低红细胞、中性粒细胞和嗜酸性粒细胞以预防血栓栓塞事件。
  • 对不明原因嗜酸性粒细胞增多患者进行髓系恶性肿瘤常见突变基因的靶向NGS可能揭示更多Leu583-Ala586DelInsSer/Gln/Pro病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The V617F mutation in the JH2 domain of Janus kinase 2 (JAK2) is an oncogenic driver in several myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera (PV). Other mutations in JAK2 have been identified in MPNs, most notably exon 12 mutations in PV. Here, we describe a novel recurrent mutation characterized by a common 4-amino-acid deletion and variable 1-amino-acid insertion (Leu583-Ala586DelInsSer/Gln/Pro) within the JH2 domain of JAK2. All 4 affected patients had eosinophilia, and both patients with Leu583-Ala586DelInsSer fulfilled diagnostic criteria of both PV and chronic eosinophilic leukemia (CEL). Computational and functional studies revealed that Leu583-Ala586DelInsSer (herein referred to as JAK2ex13InDel) deregulates JAK2 through a mechanism similar to JAK2V617F, activates signal transducer and activator of transcription 5 and extracellular signal-regulated kinase, and transforms parental Ba/F3 cells to growth factor independence. In contrast to JAK2V617F, JAK2ex13InDel does not require an exogenous homodimeric type 1 cytokine receptor to transform Ba/F3 cells and is capable of activating β common chain family cytokine receptor (interleukin-3 receptor [IL-3R], IL-5R, and granulocyte-macrophage colony stimulating factor receptor) signaling in the absence of ligand, with the maximum effect observed for IL-5R, consistent with the clinical phenotype of eosinophilia. Recognizing this new PV/CEL-overlap MPN has significant clinical implications, as both PV and CEL patients are at high risk for thrombosis, and concomitant cytoreduction of red cells, neutrophils, and eosinophils may be required for prevention of thromboembolic events. Targeted next-generation sequencing for genes recurrently mutated in myeloid malignancies in patients with unexplained eosinophilia may reveal additional cases of Leu583-Ala586DelInsSer/Gln/Pro, allowing for complete characterization of this unique MPN.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Patel AB, Franzini A, Leroy E, et al. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood. 2019. PMID: 31697804. doi:10.1182/blood.2019001385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。